Mary Ann Liebert: Twenty-Year Survival Analysis of Gene Therapy to Treat CLN2 Disease
January 10, 2025
January 10, 2025
NEW ROCHELLE, New York, Jan. 10 (TNSres) -- Mary Ann Liebert Inc. issued the following news release:
A twenty-year survival analysis published in the peer-reviewed journal Human Gene Therapy examines the results of adeno-associated virus (AAV) 2-mediated gene therapy to the central nervous system (CNS) to treat CLN2 disease. Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.182) to read the article now.
CLN2 disease (also called late infantile neuronal ceroid . . .
A twenty-year survival analysis published in the peer-reviewed journal Human Gene Therapy examines the results of adeno-associated virus (AAV) 2-mediated gene therapy to the central nervous system (CNS) to treat CLN2 disease. Click here (https://www.liebertpub.com/doi/10.1089/hum.2024.182) to read the article now.
CLN2 disease (also called late infantile neuronal ceroid . . .